Novartis agreed to acquire Excellergy for up to $2 billion in upfront and milestone payments, aiming to bolster its IgE-focused immunology strategy. Excellergy’s trifunctional allergic effector cell response inhibitors (ECRIs) are designed to neutralize IgE without triggering activation, with lead candidate Exl-111 entering Phase 1, per deal details and company statements.